Lower-Dose Cancer Immunotherapy Shows Promise for Patients in Resource-Limited Countries
Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
Image: Stat
A study presented at the American Society of Clinical Oncology meeting suggests that ultra-low doses of the PD1 inhibitor nivolumab combined with chemotherapy could improve survival rates for advanced head and neck cancer patients in poorer countries, offering a cost-effective alternative to standard treatments.
- 01The study involved 422 adults with advanced head and neck squamous cell carcinoma in India, where this cancer is highly prevalent.
- 02Patients receiving the ultra-low-dose nivolumab (TMC-I) had a median overall survival of 10.3 months, compared to 6.2 months for those on standard chemotherapy.
- 03TMC-I treatment resulted in a 46% one-year survival rate versus 23% in the control group.
- 04The new regimen also showed fewer severe side effects, with adverse events lower by about 10 percentage points compared to standard chemotherapy.
- 05There is momentum for further trials comparing low-dose and standard-dose immunotherapy, which could influence treatment protocols in both low-resource and high-resource settings.
Advertisement
In-Article Ad
Research presented at the American Society of Clinical Oncology annual meeting indicates that administering ultra-low doses of the PD1 inhibitor nivolumab, in conjunction with chemotherapy, could significantly enhance survival rates for patients with advanced head and neck squamous cell carcinoma in low-resource countries. Conducted in India, where this cancer type is the second most common, the study enrolled 422 adults and compared the new treatment, known as TMC-I, against standard chemotherapy. Results showed that patients on TMC-I had a median overall survival of 10.3 months, significantly higher than the 6.2 months for standard treatment. Additionally, about 46% of TMC-I patients survived after one year, compared to 23% in the control group, with fewer severe side effects noted. This promising data has led to discussions about further trials to optimize dosing strategies, which could ultimately reduce healthcare costs and improve patient outcomes in both low- and high-resource settings.
Advertisement
In-Article Ad
The findings could lead to broader access to effective cancer treatments in resource-limited settings, improving patient outcomes.
Advertisement
In-Article Ad
Reader Poll
Do you think ultra-low doses of immunotherapy should be more widely adopted in cancer treatment?
Connecting to poll...
More about American Society of Clinical Oncology
Revolution Medicines annonce des résultats prometteurs pour son traitement du cancer du pancréas
Investing French • May 31, 2026
New Drug Daraxonrasib Doubles Survival Time for Pancreatic Cancer Patients
Theguardian • May 31, 2026
Global Cancer Workforce Crisis: 100 Million Staff Shortfall by 2050
Theguardian • May 31, 2026
Read the original article
Visit the source for the complete story.